Comparing of Savara Inc. (SVRA) and TFF Pharmaceuticals Inc. (NASDAQ:TFFP)

Both Savara Inc. (NASDAQ:SVRA) and TFF Pharmaceuticals Inc. (NASDAQ:TFFP) are Biotechnology companies, competing one another. We will compare their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Savara Inc. 2 0.00 27.76M -1.48 0.00
TFF Pharmaceuticals Inc. 5 0.00 13.06M -0.38 0.00

Table 1 highlights Savara Inc. and TFF Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 provides Savara Inc. and TFF Pharmaceuticals Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Savara Inc. 1,260,614,867.63% -53% -38.7%
TFF Pharmaceuticals Inc. 253,100,775.19% 0% 0%


Savara Inc.’s Current Ratio and Quick Ratio are 13.1 and 13.1 respectively. The Current Ratio and Quick Ratio of its competitor TFF Pharmaceuticals Inc. are 8.4 and 8.4 respectively. Savara Inc. therefore has a better chance of paying off short and long-term obligations compared to TFF Pharmaceuticals Inc.

Insider and Institutional Ownership

The shares of both Savara Inc. and TFF Pharmaceuticals Inc. are owned by institutional investors at 42.9% and 0% respectively. About 0.5% of Savara Inc.’s share are owned by insiders. Comparatively, insiders own roughly 22.9% of TFF Pharmaceuticals Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Savara Inc. -11.11% 22.08% -52.54% -89.85% -85.79% -85.2%
TFF Pharmaceuticals Inc. -1.71% -1.52% 0% 0% 0% 1.97%

For the past year Savara Inc. had bearish trend while TFF Pharmaceuticals Inc. had bullish trend.


TFF Pharmaceuticals Inc. beats Savara Inc. on 5 of the 9 factors.

Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its product pipeline comprises AeroVanc, a Phase III ready inhaled formulation of vancomycin for the treatment of persistent methicillin-resistant staphylococcus aureus and lung infection in cystic fibrosis patients; Molgradex, a Phase II/III stage inhaled granulocyte-macrophage colony-stimulating factor for the treatment of autoimmune pulmonary alveolar proteinosis; and Aironite, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction. The company is headquartered in Austin, Texas.